August 28, 2012 — NDS Surgical Imaging (NDSsi) is now shipping its new Dome GX4MP radiology display, a 30-inch widescreen model offering multimodality viewing in both color and grayscale.

Cardiac coronary calcium scoring.

August 27, 2012 — A recent multi-center study, led by researchers from Wake Forest School of Medicine and published in the Journal of the American Medical Association (JAMA) has indicated that computed tomography (CT) scanning of the heart and measuring the coronary artery calcium (CAC) score is the most accurate predictor of cardiovascular disease for individuals at intermediate risk for heart disease.

August 27, 2012 — Positron Corp., a molecular imaging healthcare company, announced the submission of a drug master file (DMF) with the U.S. Food and Drug Administration (FDA) for the production of active pharmaceutical ingredient- (API) grade strontium-82 through its wholly owned subsidiary, Manhattan Isotope Technology LLC (MIT).
meaningful use, Stage 2, cardiology, radiology, CPOE, clinical decision support

There are some key requirements specifically aimed at imaging and radiology included in the Stage 2 meaningful use requirements released Aug. 23 by the Department of Health and Human Services (HHS). HHS fielded many concerns and questions about these requirements and offered answers in the 642-page document.

August 24, 2012 — The Stage 2 meaningful use requirements for electronic health records (EHRs) were released Aug. 23 by the Department of Health and Human Services (HHS) and the Centers for Medicare and Medicaid (CMS). The rule specifies criteria that eligible professionals (EPs), eligible hospitals and critical access hospitals (CAHs) must meet in order to qualify for CMS EHR incentive payments. In addition, it specifies payment reductions for EPs and facilities failing to demonstrate meaningful use of certified EHR technology.

August 23, 2012 — The U.S. Food and Drug Administration (FDA) has cleared Toshiba’s Aquilion RXL Edition CT system. The system reconstructs images faster and includes the latest dose reduction technologies, providing faster, safer information to physicians and patients.

August 23, 2012 — Decision Resources, a research and advisory firm for pharmaceutical and healthcare issues, finds that the 12-month post-hospital acute coronary syndrome market will initially contract from just under $2 billion in 2011 to about $1.6 billion in 2013, mainly as a result of the U.S. genericization of clopidogrel (Bristol-Myers Squibb/Sanofi’s Plavix) in 2012. Decision Resources forecasts that the post-hospital acute coronary syndrome antiplatelet/anticoagulant market will then expand to almost $2.7 billion in 2021, owing largely to uptake of oral agents with novel modes of action, such as AstraZeneca’s ticagrelor (Brilinta) and the CETP inhibitors, Merck’s anacetrapib and Eli Lilly’s evacetrapib.

Philips Healthcare and Corindus Vascular Robotics announced a distribution agreement for Corindus’ CorPath 200 System. The system was recently cleared by the U.S. Food and Drug Administration (FDA) and is the world's first robotic-assisted system for the minimally invasive as percutaneous coronary intervention (PCI) of obstructed coronary arteries.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now